Therapeutic Drug Monitoring of Dalbavancin Treatment in Severe Necrotizing Fasciitis in 3 Critically Ill Patients: A Grand Round.
Ther Drug Monit
; 42(2): 165-168, 2020 04.
Article
in English
| MEDLINE | ID: covidwho-11505
ABSTRACT
BACKGROUND:
Dalbavancin, albeit indicated for the treatment of skin structure infections, is used for a much wider range of infections. This drug is characterized by a long half-life (more than 200 hours), a favorable safety profile, and an activity against a wide array of gram-positive organisms, including several strains of Staphylococci and Enterococci.METHODS:
In this study, we presented 3 cases of critically ill patients treated with dalbavancin. All patients were therapeutically monitored for plasma dalbavancin concentrations; ultrafiltrate dalbavancin concentrations were assessed in a patient undergoing continuous renal-replacement therapy. Dalbavancin concentrations were measured using a validated liquid chromatographic method coupled with mass spectrometry.RESULTS:
All 3 severely ill patients experiencing necrotizing fasciitis were successfully treated during the acute phase with dalbavancin. Dalbavancin clearance in patient 3 (0.334 L/h) was considerably increased compared with values measured in the other 2 patients (0.054 and 0.075 L/h) and with data reported in the literature (0.04-0.06 L/h).CONCLUSIONS:
Our case reports presented preliminary evidence that dalbavancin can be considered a therapeutic option for necrotizing fasciitis in intensive care unit patients. The role of hypoalbuminemia during dalbavancin exposure merits further investigation.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Drug Monitoring
/
Critical Illness
/
Teicoplanin
/
Fasciitis, Necrotizing
/
Anti-Bacterial Agents
Type of study:
Case report
/
Prognostic study
Limits:
Adult
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Ther Drug Monit
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS